Centogene N.V. Common Shares - CNTG STOCK NEWS

Centogene N.V. (Nasdaq: CNTG) reported a slight revenue decrease of 0.4% for H1 2020, totaling €21.8 million. Key developments include a follow-on equity offering raising €24 million and the FDA Emergency Use Authorization for its CentoFast-SARS-CoV-2 RT-PCR test. The company anticipates full-year revenues between €60 and €65 million. Despite the COVID-19 pandemic's impact, diagnostics revenue rose 0.8% to €13.3 million, while pharmaceutical revenue fell 2.4% to €8.5 million. G&A expenses surged by 36.4%, impacting profitability, resulting in a comprehensive loss of €19 million.

CENTOGENE has expanded its SARS-CoV-2 testing solutions by opening a new COVID-19 testing facility at Düsseldorf Airport. This facility caters to travelers and the general public, offering PCR tests from 7:00 a.m. to 7:00 p.m. Results will be delivered within 24 hours via a secure digital platform. The company aims to support public health and economic recovery through accessible testing solutions. CENTOGENE's testing capabilities are already established at Frankfurt and Hamburg airports, emphasizing their commitment to broad, preventive testing amidst ongoing global travel challenges.

Centogene N.V. (NASDAQ: CNTG) will release its financial results for the six months ending June 30, 2020, on September 23, 2020, followed by a conference call at 8 a.m. ET. The company specializes in rare diseases, leveraging real-world clinical and genetic data to support patients and pharmaceutical partners. As of March 31, 2020, Centogene's platform contained approximately 3.0 billion data points from over 530,000 patients and collaborated with 39 pharmaceutical partners on more than 45 rare diseases.

CENTOGENE has expanded its COVID-19 testing capacity at Frankfurt Airport, enhancing its Walk-In Testing Facility. This new sampling area aims to support safe travel as international borders reopen. Passengers can access tests conveniently near the terminal, with results delivered via a secure digital platform. CENTOGENE emphasizes the importance of widespread testing for safe air travel, despite the cessation of free testing by the German Ministry of Health. The facility also accommodates non-travelers and integrates with the Corona-Warn-App for a smooth testing experience.

Centogene N.V. (Nasdaq: CNTG) has published a significant study in the European Journal of Human Genetics, highlighting genome sequencing (GS) as a crucial first-line diagnostic tool for rare diseases. The research involved over 1,000 cases, demonstrating GS's ability to provide faster, more reliable diagnoses compared to previous exome sequencing, thereby potentially reducing healthcare costs. CEO Prof. Arndt Rolfs emphasized the company's commitment to improving diagnostic processes. The study underscores the clinical utility of GS in avoiding delays associated with traditional stepwise testing.

Centogene N.V. (Nasdaq: CNTG) and Evotec SE have expanded their drug discovery partnership focused on Gaucher disease, a genetic lysosomal storage disorder. The collaboration aims to develop innovative treatments by leveraging Centogene's expertise in rare hereditary diseases and Evotec's drug discovery capabilities. This partnership builds on a previous agreement from 2018 and aims to utilize real-world clinical data and induced pluripotent stem cell technology for medical solutions targeted at Gaucher patients, addressing an unmet medical need in the rare disease sector.

CENTOGENE expands its SARS-CoV-2 testing services to Hamburg Airport, following the launch of a similar facility at Frankfurt Airport in June 2020. The new walk-in testing center caters to passengers departing and returning from non-risk countries, as well as the general public. Operating daily from 6:00 a.m. to 8:00 p.m. CEST, the facility aims to facilitate safe travel amid the pandemic. CENTOGENE's PCR tests have received FDA Emergency Use Authorization and are designed to detect active SARS-CoV-2 infections, marking an important step toward restoring air travel.

Centogene N.V. (Nasdaq: CNTG) has released CentoMD® 5.8, an updated curated mutation database for rare diseases. The database now includes over 12.7 million unique variants and has analyzed more than 430,000 cases globally. This version enhances the company's commitment to improving diagnosis and treatment for rare disease patients, linking more than 199,000 individuals to clinical data. Additionally, an update to CentoLSD™, a database for lysosomal storage diseases, is also noted. Centogene aims to leverage real-world data to accelerate orphan drug development.

CENTOGENE has launched its validated COVID-19 test kit, CentoKit-19™, on Amazon in Germany, marking the first of its kind available through the platform. This testing solution aims to enhance access to COVID-19 testing, enabling individuals to receive results efficiently through digital reports. The test is validated according to WHO guidelines and offers a comprehensive at-home testing experience, including all necessary materials for sampling and return. The initiative supports public health efforts to manage the pandemic by facilitating early detection and breaking infection chains.